TaHO Pharma Clears FDA Hurdle for Antithrombotic Oral Film BEQIA

TaHO Pharmaceuticals, a Taiwanese biotech company listed on the Taipei Exchange (6467.TW), has cleared a significant hurdle in the development of its antithrombotic oral film drug BEQIA. The company announced that its New Drug Application (NDA) for BEQIA officially entered substantive review by the U.S. Food and Drug Administration (FDA) on August 21.

BEQIA is the world's first Apixaban antithrombotic oral film, developed using TaHO Pharmaceuticals' proprietary TDS platform technology. The originator drug Eliquis posted U.S. sales of $29.2 billion in 2025, with more than 70% of usage for atrial fibrillation patients to prevent blood clot formation.

Notably, the price cuts under the Inflation Reduction Act led to a substantial increase in new prescriptions as patients who could not afford the medication could now access it. Insurance companies pay $2,772 for a full year of medication, significantly lower than the $46,700 annual care cost that would be incurred in the event of a stroke.

TaHO Pharmaceuticals has signed confidentiality agreements with dozens of pharmaceutical companies across Europe, the U.S., Australia/New Zealand, Latin America, and Asia, entering substantive licensing negotiations. The subsequent approval timeline and licensing progress will serve as key operational indicators for the company's performance.